I. Background
Among Chinese patients with non‑small cell lung cancer (NSCLC), over 50% carry epidermal growth factor receptor (EGFR) mutations, with exon 19 deletion (ex19del) and exon 21 L858R point mutation being the most common. First‑, second‑, and third‑generation EGFR‑tyrosine kinase inhibitors (EGFR‑TKIs) have significantly improved patient outcomes, but patients with EGFR L858R mutations consistently show inferior responses to existing EGFR‑TKIs compared with ex19del patients — with shorter progression‑free survival (PFS) and limited overall survival (OS) benefit, representing a clear unmet clinical need.
Mefatinib is a novel oral, highly selective second‑generation EGFR‑TKI. Previous clinical studies have demonstrated its potent antitumor activity against common and atypical EGFR mutations. This study was led by the team of Prof. Caicun Zhou from Shanghai East Hospital, Tongji University, and Prof. Kai Wang from the Second Affiliated Hospital of Zhejiang University School of Medicine.
II. Study Design
Type: Randomized, double‑blind, double‑dummy, multicenter phase 3 superiority trial.
Enrollment: 336 Chinese patients with advanced non‑squamous NSCLC harboring EGFR L858R or ex19del mutations, aged 18–75 years, ECOG PS 0–1, with no prior systemic therapy.
Grouping and dosing:
Mefatinib group (n=223): mefatinib 60 mg + gefitinib placebo, once daily;
Gefitinib group (n=113): gefitinib 250 mg + mefatinib placebo, once daily.
Stratification factor: EGFR mutation type (ex19del vs. L858R).
Primary endpoint: PFS assessed by independent review committee (IRC).
Secondary endpoints: Investigator‑assessed PFS, OS, objective response rate (ORR), disease control rate (DCR), duration of response (DoR), health‑related quality of life (HRQoL), and safety.
III. Results
1. Primary endpoint: IRC‑assessed PFS
|
Endpoint |
Meigufatinib Group |
Gefitinib Group |
HR (95% CI) |
P |
|
Median PFS |
13.7 (11.0-15.2) |
9.7 (8.3-12.4) |
0.68 (0.53-0.87) |
0.002 |
Mefatinib significantly prolonged PFS, reducing the risk of disease progression or death by 32%.
2. Key subgroup: EGFR L858R mutation patients
|
Subgroup |
Mafatinib Group |
Gefitinib Group |
HR (95% CI) |
P-value |
|
L858R (n=172) |
13.7 (9.7-15.3) |
8.3 (7.0-9.7) |
0.55 (0.38-0.78) |
0.001 |
|
ex19del (n=164) |
12.6 (11.0-15.2) |
12.5 (9.6-15.1) |
0.83 (0.58-1.19) |
0.307 |
In the L858R subgroup, the PFS benefit with mefatinib was particularly pronounced (HR=0.55), whereas in the ex19del subgroup, the two regimens showed comparable efficacy.
3. Secondary efficacy endpoints (IRC‑assessed)
|
Endpoint |
Meifanertinib Group |
Gefitinib Group |
Statistical Value |
|
ORR (%) |
81.2 |
77.9 |
OR=1.23 (0.70-2.14), P=0.477 |
|
DCR (%) |
89.7 |
90.3 |
P=0.868 |
|
Median DoR (months) |
12.5 (11.0-14.0) |
9.7 (7.0-11.1) |
HR=0.68 (0.52-0.91), P=0.008 |
|
L858R subgroup |
12.5 (9.7-15.2) |
8.2 (6.7-9.7) |
HR=0.54 (0.36-0.81), P=0.003 |
DoR was significantly prolonged in the mefatinib group, with more prominent benefit in the L858R subgroup.
4. Overall survival (OS)
OS data were not yet mature. Median OS was 35.4 months in the mefatinib group vs. 33.3 months in the gefitinib group (HR=0.90, P=0.577). The 30‑month OS rate was 60.2% for mefatinib vs. 54.3% for gefitinib. In the L858R subgroup, the 30‑month OS rate was 56.6% for mefatinib vs. 43.7% for gefitinib, showing a trend toward benefit.
5. Safety
|
Indicator |
Meivanertinib Group |
Gefitinib Group |
|
≥ Grade 3 Treatment-Related |
45.7 |
24.8 |
|
Serious TRAE |
8.5 |
10.6 |
|
TRAE leading to permanent |
4 |
1.8 |
|
TRAE leading to dose |
30.9 |
23.0 |
|
Common ≥ Grade 3 TRAE |
Diarrhea (20.0), |
ALT increased (7.1), |
Gastrointestinal and skin toxicities were more common with mefatinib, while liver enzyme elevations were more common with gefitinib. Overall tolerability was good, consistent with previous studies, with no new safety signals identified.
IV. Study Highlights
This is the first head‑to‑head phase 3 study comparing mefatinib with gefitinib, confirming that mefatinib as first‑line therapy for EGFR‑mutant advanced NSCLC provides significantly superior PFS over gefitinib (13.7 vs. 9.7 months, HR=0.68).
The advantage was particularly prominent in the L858R subgroup, with a PFS HR of 0.55 and a DoR HR of 0.54, and a 12.9% absolute improvement in the 30‑month OS rate — filling the treatment gap for this difficult‑to‑treat subgroup.
The treatment sequencing value is clear: the incidence of T790M resistance mutation after mefatinib treatment is approximately 42%, allowing subsequent sequencing with third‑generation EGFR‑TKIs and potentially delaying the need for chemotherapy.
Mefatinib was approved in China in October 2025 for the treatment of EGFR L858R‑mutant NSCLC, offering direct clinical applicability.
V. Conclusion
Mefatinib as first‑line therapy for EGFR‑mutant advanced non‑squamous NSCLC demonstrated significantly superior overall efficacy and good tolerability compared with gefitinib. Its greatest clinical value lies in the L858R mutation subtype, where it significantly prolongs survival and enhances the durability of response, providing a new preferred treatment option for this poor‑prognosis patient population and refining the clinical treatment landscape for EGFR‑TKIs.
References:
[1] Yu J, Xiong A, Wang Q, et al. Mefatinib versus gefitinib as a first‑line treatment for EGFR‑mutated non‑small cell lung cancer: a randomized, double‑blind, multicenter phase III study. Signal Transduct Target Ther. 2026;11(1):324.